Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-016-3165-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter to the editor: anticoagulation, photoselective vaporization of the prostate and safety: a propensity score-matched study.
World J Urol
December 2024
School of Pharmacy, Hubei University of Traditional Chinese Medicine, Wuhan, 430065, China.
Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, India.
Patient Safety Climate in Danish Primary Care: Adaption and Validation of the Danish Safety Attitudes Questionnaire (SAQ-DK-PRIM) [Response to Letter].
Clin Epidemiol
December 2024
Aalborg University Hospital, Psychiatry, Aalborg, Denmark.
Response to Reader Comment on: "Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir".
Toxicol Sci
December 2024
Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, Merck & Co. Inc, Rahway, New Jersey, USA.
Comment to: "Efficacy and Safety of Hyaluronic Acid Combined with Botulinum Toxin Type A in the Treatment of Midcheek Groove: A Prospective Study".
Aesthetic Plast Surg
December 2024
Plastic and Reconstructive Microsurgery - Careggi University Hospital, Viale Giacomo Matteotti 42, 50132, Florence, Italy.
Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!